비침습적 암 진단 : 기술과 세계 시장

The global market for noninvasive cancer diagnostic technologies is expected to grow from $119.9 billion in 2025 and is projected to reach $165.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.6% during the forecast period of 2025 to 2030.

The North American market for noninvasive cancer diagnostic technologies is expected to grow from $48.6 billion in 2025 and is projected to reach $68.5 billion by the end of 2030, at a CAGR of 7.1% during the forecast period of 2025 to 2030.

The European market for noninvasive cancer diagnostic technologies is expected to grow from $29.4 billion in 2025 and is projected to reach $39.3 billion by the end of 2030, at a CAGR of 6% during the forecast period of 2025 to 2030.

Report Scope

The report provides an overview of noninvasive cancer diagnostics technologies and global markets, with a detailed analysis of current market trends. It presents global revenue ($ Million) for the base year 2024, estimated data for 2025, and forecast data for 2026 through 2030. It also includes detailed insights into revenues, forecasts, product indications, and market segmentation. The market is segmented by cancer type, technologies, and end user. Regional coverage encompasses North America, Europe, the Asia-Pacific, and South Africa, with detailed analyses of the Middle East and Africa (MEA), including major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India.

This report provides a detailed overview of noninvasive cancer diagnostic products currently available in the market. It also examines cancer incidence and mortality statistics to provide context for market demand, outlines key challenges limiting the widespread adoption of these technologies, and highlights recent innovations shaping the next generation of diagnostic tools. It provides an in-depth overview of industry dynamics, including opportunities, constraints, and the competitive environment, highlighting both international leaders and smaller regional players active in the market.

The report offers a competitive landscape and includes information on major suppliers and manufacturers, describing their core products and strategic focus areas. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio, and recent developments in major companies.

Report Includes

• 71 data tables and 63 additional tables
• In-depth analysis of the global market for noninvasive cancer diagnostics and technologies
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by technology, cancer type, end user and region
• Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations and prospects, and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Review of next-generation novel noninvasive cancer molecular diagnostics platforms, current methods and future perspectives on early-stage cancer detection, and emerging biomarker technologies for diagnosis and treatment of cancer
• Evaluation of the current products, their indications and availability for all the market segments identified, and intended clinical applications
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Profiles of the leading global companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Labcorp Holdings Inc., and Abbott

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of the Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Diagnostic Imaging Technologies
• Advanced Noninvasive Approaches
• Conventional Cancer Screening, Diagnostic Assays and Tests
• Porter's Five Forces Analysis
• Competitive Rivalry (High)
• Potential for New Entrant (Moderate to High)
• Threat of Substitutes (Moderate)
• Bargaining Power of Suppliers (Moderate)
• Bargaining Power of Buyers (Hospitals, Diagnostic Labs, Payers, and Patients) (High)
• Macroeconomic Factors Analysis
• Rising Disease Burden and Growing Demand for Diagnostics
• Healthcare Spending and Payer Dynamics
• Macroeconomic Growth and Funding Environment
• Technological Advances
• Impact of U.S. Tariffs

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Increasing Prevalence of Cancer
• Growing Adoption of Liquid Biopsy Technologies
• Shift Toward Early and Preventive Diagnosis
• Rising Healthcare Expenditure and R&D Funding
• Market Restraints
• High Cost of Advanced Diagnostic Technologies
• Low Awareness in Developing Regions
• Market Opportunities
• AI-Enabled Diagnostics and Digital Pathology
• Emerging Markets with Underserved Screening Populations
• Market Challenges
• Shortage of Radiologists
• False-Positive and False-Negative Results

Chapter 4 Regulatory Landscape

• U.S. Approval Process
• EU Approval Process
• Asia-Pacific Approval Process
• Japan
• China
• Australia
• India

Chapter 5 Emerging Technologiesand Developments

• Key Takeaways
• Multi-Cancer Early Detection (MCED) Tests
• Radiomics Technology
• Urine-Based Molecular Tests
• Breath-Based Diagnostics (Volatile Organic Compounds)
• Multi-Omics Diagnostic Platforms
• Patent Analysis
• Key Findings

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Market Analysis, by Cancer Type
• Key Takeaways
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Cervical Cancer
• Stomach Cancer
• Liver Cancer
• Esophageal Cancer
• Bladder Cancer
• All Other Cancers
• Market Analysis, by Technology Type
• Key Takeaways
• Diagnostic Imaging Technologies
• Advanced Noninvasive Approaches
• Conventional Noninvasive Cancer Screening, Diagnostic Assays and Tests
• Market Analysis, by End User
• Key Takeaways
• Hospitals
• Academic Institutes
• Cancer Institutes
• Diagnostic Centers
• Government and Private Research Institutes
• Pharmaceutical Companies
• Contract Research Organizations
• Geographic Breakdown
• Market Analysis, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Key Takeaways
• Leading Companies in Global Noninvasive Cancer Diagnostics Market
• Key Developments and Strategies
• Partnerships and Collaborations
• Acquisitions
• Key Strategic Activities and Developments
• Product Launches and Regulatory Approvals

Chapter 8 Sustainability in Global Noninvasive Cancer Diagnostics Market: An ESG Perspective

• Introduction to ESG
• Major Manufacturers: ESG Efforts
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBOTT
• BD
• BIO-RAD LABORATORIES INC.
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• GUARDANT HEALTH INC.
• HOLOGIC INC.
• ILLUMINA INC.
• KONINKLIJKE PHILIPS N.V.
• LABCORP
• LEICA BIOSYSTEMS NUSSLOCH GMBH
• QIAGEN
• REVVITY
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• Few Emerging Startups/Market Disruptors